ADEZA GETS FDA PRIORITY REVIEW STATUS FOR GESTIVA

A A

Adeza, a medical technology company located in Sunnyvale, California, announced that the US Food and Drug Administration (FDA) has granted the company's New Drug Application (NDA) for Gestiva Priority Review status. A Priority Review designation sets a six-month goal for review by the FDA. Priority Review is granted to product candidates that, if approved, would provide a significant improvement in the treatment, diagnosis or prevention of a disease.

Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=34155§ionid=)